EcoDrugPlus

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSRROG00000040371
Gene Symbol: PTGS2
4 Cross references
237 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSRROG00000037748
Gene Symbol: PSMA1
4 Cross references
245 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSRROG00000031466
Gene Symbol: PSMA2
4 Cross references
161 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSRROG00000040700
Gene Symbol: PSMA3
4 Cross references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSRROG00000040268
Gene Symbol: PSMA4
4 Cross references
241 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSRROG00000039802
Gene Symbol: PSMA5
4 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSRROG00000043152
Gene Symbol: PSMA6
4 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 7

Ensembl ID : ENSRROG00000043126
Gene Symbol: PSMA7
2 Cross references
152 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSRROG00000014601
Gene Symbol: PSMA8
4 Cross references
196 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSRROG00000036198
Gene Symbol: PSMB1
4 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSRROG00000003928
Gene Symbol: PSMB10
4 Cross references
171 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSRROG00000029102
Gene Symbol: PSMB2
4 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).